.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Recent data from the FOURIER trial have addressed clinical concerns regarding low lipoprotein(a) safety in patients with atherosclerotic cardiovascular disease. While high levels of Lipoprotein(a) drive heart disease risk, many physicians worry about potential side effects from extremely low concentrations. Consequently, this secondary analysis focused on safety outcomes like bleeding and cognitive function in over 25,000 participants.
The study found no link between low Lp(a) levels and risks of haemorrhagic stroke, serious bleeding, or malignancy. Moreover, participants with levels as low as 13 nmol/L showed no increased incidence of atrial fibrillation or neurocognitive events. These results provide significant reassurance to clinicians. Specifically, the data suggest that aggressive lowering of this lipoprotein does not compromise neurological or vascular integrity.
However, the relationship with diabetes mellitus remains complex. While a lower baseline concentration was associated with a higher prevalence of diabetes, it did not predict a higher risk of developing new-onset diabetes during the trial. Therefore, the metabolic profile of these patients requires monitoring, yet the overall safety remains high. Furthermore, these findings support the continued development of targeted Lp(a) therapies.
Data show that while patients with naturally low Lp(a) may have a higher prevalence of diabetes at baseline, lowering Lp(a) with medication does not appear to increase the risk of developing new-onset diabetes.
Yes, the FOURIER trial indicates that very low levels of Lp(a) are not associated with increased risks of stroke, bleeding, cancer, or cognitive decline, supporting its long-term safety profile.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional recommendation. Always consult a qualified healthcare provider for personal health concerns. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A comprehensive analysis of the FOURIER trial confirms that low lipoprotein(a) levels are generally safe and do not increase risks of stroke or new diabetes...
3 months ago
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
The All-India Food Processors' Association has approached the Supreme Court to oppose FSSAI's proposed per-100g benchmark for front-of-pack warning labels, advocating instead for a per-serving threshold. We explore the regulatory showdown, nutritional evidence, and implications for clinical lifestyle counseling.
Today
